Notice Type
Departmental
Notice Title

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
Product: Redipred
Active Ingredient: Prednisolone sodium phosphate 6.72mg/mL equivalent to Prednisolone 5mg/mL
Dosage Form: Oral solution
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturers: Aspen Pharma Pty Limited, Melbourne, Australia
Lipa Pharmaceuticals Limited, Sydney, Australia
Product: Reyataz
Active Ingredient: Atazanavir sulfate 113.9mg equivalent to Atazanavir 100mg
Dosage Form: Capsule
New Zealand Sponsor: Bristol-Myers Squibb (NZ) Limited
Manufacturer: Bristol-Myers Squibb Company, Indiana, United States of America
Product: Reyataz
Active Ingredient: Atazanavir sulfate 170.84mg equivalent to Atazanavir 150mg
Dosage Form: Capsule
New Zealand Sponsor: Bristol-Myers Squibb (NZ) Limited
Manufacturer: Bristol-Myers Squibb Company, Indiana, United States of America
Product: Reyataz
Active Ingredient: Atazanavir sulfate 227.79mg equivalent to Atazanavir 200mg
Dosage Form: Capsule
New Zealand Sponsor: Bristol-Myers Squibb (NZ) Limited
Manufacturer: Bristol-Myers Squibb Company, Indiana, United States of America
Product: Reyataz
Active Ingredient: Atazanavir sulfate 341.69mg equivalent to Atazanavir 300mg
Dosage Form: Capsule
New Zealand Sponsor: Bristol-Myers Squibb (NZ) Limited
Manufacturer: Bristol-Myers Squibb Company, Indiana, United States of America
Dated this 10th day of April 2014.
STEWART JESSAMINE, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).